What is it about?

Scientists have discovered how certain cancer cells may escape detection by our immune system. They found that an enzyme called ADAM17, which is present at high levels in some cancers, can destroy an important immune system protein called interferon-gamma. This protein normally helps our body fight cancer in two ways: it activates immune cells to attack tumors, and it prevents cancer from spreading to bones. When cancer cells produce high amounts of ADAM17, they can break down interferon-gamma, making it harder for the immune system to detect and fight the cancer. This discovery is particularly relevant for breast cancer, where researchers found that cancer cells can quickly destroy interferon-gamma using ADAM17. The study also shows that blocking ADAM17 could help protect interferon-gamma, suggesting a potential new approach for cancer treatment. This could be especially important for preventing cancer from spreading to bones, a common complication in breast cancer. This finding helps explain why some cancers become more aggressive and resistant to the body's natural defenses. It also points to ADAM17 as a promising target for new cancer therapies that could help the immune system better fight cancer.

Featured Image

Why is it important?

This discovery is groundbreaking and important for several key reasons: 1. First Identification of This Mechanism - This is the first study to show how interferon-gamma, a crucial cancer-fighting protein, can be destroyed outside of cells - It reveals a previously unknown way that cancer cells can evade the immune system 2. Immediate Clinical Relevance - The findings directly explain why some breast cancers become more aggressive - It helps us understand why cancer treatments that rely on immune responses sometimes fail - The research identifies ADAM17 as a promising new target for cancer therapy 3. Multiple Health Applications - The discovery is particularly relevant for breast cancer treatment - It provides new insights into how cancers spread to bones - The findings could lead to better treatments for both primary tumors and cancer that has spread 4. Practical Treatment Potential - The study shows that blocking ADAM17 can protect interferon-gamma - This suggests a straightforward approach to improving cancer immunotherapy - It offers a new strategy for preventing cancer from spreading to bones, a common and serious complication 5. Broader Scientific Impact - The research connects different aspects of cancer biology: immune evasion, tumor progression, and bone metastasis - It provides a new framework for understanding how cancers evolve to escape immune surveillance - The findings could influence how we approach cancer immunotherapy in general This work is timely because: - It comes as immunotherapy is becoming a major focus in cancer treatment - It addresses the crucial question of why some cancers resist immune system attacks - It offers a potential solution to improving existing cancer treatments The research opens up new possibilities for: - Developing more effective cancer treatments - Creating better combination therapies - Preventing cancer spread to bones - Improving patient outcomes in aggressive cancers

Perspectives

As the primary investigator of this study, I'm particularly excited about how our discovery bridges several critical areas of cancer biology that were previously viewed separately. What started as an investigation into a single enzyme led us to uncover a fascinating mechanism that connects tumor immunology, cancer progression, and bone metastasis. What makes this discovery especially meaningful to me is its potential practical impact. Throughout my research career, I've seen many cancer patients struggle with bone metastases, which can be incredibly painful and difficult to treat. Finding that ADAM17 might be the key player in this process - not just in cancer growth but also in helping cancer evade the immune system - feels like uncovering a crucial piece of a complex puzzle. The most surprising aspect of our research was discovering how quickly cancer cells can disable interferon-gamma. This finding really shifted my perspective on how cancer cells interact with the immune system. It's not just about cancer cells hiding from immune detection; they're actively dismantling our body's natural defense mechanisms. I'm particularly proud that our work opens up a new therapeutic avenue. When we found that blocking ADAM17 could protect interferon-gamma, it felt like we'd not only identified a problem but also pointed toward a solution. This kind of practical application potential is what drives me as a scientist. Looking ahead, I'm excited about the possibilities this research opens up. While we focused on breast cancer, the mechanisms we uncovered could be relevant to many other types of cancer. I believe our findings could help explain why some immunotherapies work better than others and potentially lead to more effective combination treatments. Most importantly, this research reminds us that even well-studied aspects of cancer biology can still hold surprising secrets. It reinforces my belief that careful observation and willingness to follow unexpected results can lead to significant discoveries that might ultimately help cancer patients.

Hiroyuki Kanzaki
Tsurumi University

Read the Original

This page is a summary of: A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma, Scientific Reports, August 2016, Nature,
DOI: 10.1038/srep32259.
You can read the full text:

Read

Contributors

The following have contributed to this page